You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.09)︱南航子公司實行啟動混改,擬出讓不超49.5%股權;弘陽地產前8個月銷售480億元
格隆匯 09-09 22:58

【業績預告】

毅興行(01047.HK)年度預虧不少於600萬港元

【運營數據】

弘陽地產(01996.HK)前8個月銷售額達480.1億元 同比增長23%

遠洋集團(03377.HK):1-8月累計協議銷售額同比下降20%至600億元

晨訊科技(02000.HK)前8月收入同比減少7.9%至6.8億港元

中廣核新能源(01811.HK)8月完成發電量1152.2吉瓦時 同比減少16.2%

天立教育(01773.HK)校網內K-12學校入讀人數大增44.5%至5.66萬人

江山控股(00295.HK):1-8月太陽能發電站發電量約128.57萬兆瓦時

【訴訟處罰】

平安證券集團控股(00231.HK)收到傳訊令狀被索償7500萬港元

【增減持】

上海電氣(02727.HK)持有贏合科技28.28%的股份 為其控股股東

晨鳴紙業(01812.HK)控股股東累計增持1782萬股A股 增持計劃實施完成

德林控股(01709.HK)購買771萬股贏家時尚(03709.HK)股份

【併購出售】

中國南方航空股份(01055.HK):南航物流擬掛牌引資 釋放不超49.5%股權

中盈集團控股(00766.HK)股價異動 主要股東樑毅文出售約3.28億股

上海電氣(02727.HK)控股子公司擬轉讓天沃恩科100%股權予太平洋機電

綠地香港(00337.HK)擬4.78億元收購浙江桐鄉物業

加達控股(01620.HK)9月8日出售合共750萬股信義股份

【重大事項】

歌禮制藥-B(01672.HK)與Galmed拓展NASH管線開展Aramchol與ASC41聯合用藥研究

麗珠醫藥(01513.HK):獲藥物臨牀試驗批准通知書

復星醫藥(02196.HK):貝伐珠單抗注射液獲國家藥監局藥品註冊審評受理

君實生物(01877.HK)成立一間合資聯合開發CD39藥物

縱橫遊控股(08069.HK):Vpon Inc.獲得4000萬美元C輪融資

復宏漢霖-B(02696.HK):HLX04(重組抗VEGF人源化單克隆抗體注射液)上市註冊申請獲受理

上海醫藥(02607.HK):注射用LT3001獲得臨牀試驗批准通知書

上海實業環境(00807.HK):黃石凱迪水務實行增資擴股 註冊股本增至7300萬元

鷹力投資(00901.HK)與華豐籤備忘錄,擬合作成立華豐黃金股權投資併購基金

【回購註銷】

中國旺旺(00151.HK)9月9日耗資5274.73萬港元回購969.30萬股

復星國際(00656.HK)9月9日耗資2269.55萬港元回購264萬股

合生創展集團(00754.HK)9月9日耗資1324.36萬港元回購80萬股

金鷹商貿集團(03308.HK)9月9日耗資247.92萬港元回購35.1萬股

澳能建設(01183.HK):動用股份購回授權 購回不超5000萬股

捷榮國際控股(02119.HK)9月9日耗資186.65萬港元回購168.2萬股

中國水務(00855.HK)9月9日耗資156.91萬港元回購26.2萬股

陸氏集團(越南)(00366.HK)9月9日耗資334.28萬港元回購274萬股

富智康集團(02038.HK)9月9日耗資145.6萬港元回購160萬股

【股權激勵】

A8新媒體(00800.HK)授出1998.2萬份購股權

法諾集團(08153.HK)授出4.9億份購股權

佐丹奴國際(00709.HK)授出7731萬份購股權 行使價每股1.39港元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account